Radiomic model versus R.E.N.A.L. nephrometry score for predicting the likelihood of undergoing partial nephrectomy in clear cell renal cell carcinoma.
Authors
Affiliations (3)
Affiliations (3)
- Department of Urology, Jiangning Clinical Medical College of Kangda College of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract
To develop a CT-based radiomic model for predicting partial nephrectomy (PN) in clear cell renal cell carcinoma (ccRCC) and compare it with the R.E.N.A.L. Nephrometry Score (RNS). This retrospective study included 413 ccRCC patients who underwent PN or radical nephrectomy. The RNS was calculated from preoperative CT. Radiomic features were extracted from corticomedullary-phase CT. Reproducibility was assessed using intraclass correlation coefficients (ICCs). LASSO regression was used for feature selection and Rad-score construction. Multivariable logistic regression models were built based on the total RNS sum and the Rad-score. Performance was evaluated by AUC, calibration, and decision curve analysis. Of 1210 extracted features (after excluding general_info fields), 851 showed good to excellent reproducibility (ICC > 0.75). The radiomic model (6 selected features) achieved an AUC of 0.886 (95% CI: 0.81-0.91) in the internal validation cohort, significantly outperforming the RNS model (AUC = 0.793, 95% CI: 0.72-0.85; DeLong test, P = 0.015). The radiomic model also demonstrated better calibration (Brier score: 0.11 vs. 0.16) and higher clinical net benefit. SHAP analysis identified tumor size and texture heterogeneity as the strongest predictors. A CT-based radiomic model provides superior accuracy over the RNS for preoperatively predicting PN likelihood in ccRCC and holds significant potential to augment surgical decision-making and personalize treatment planning. Prospective multi-center validation is warranted before routine clinical adoption.